BioCentury | Feb 29, 2020
Translation in Brief

Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation

Genentech identifies blood as source of antitumor T cells   In a Nature article , a Genentech Inc. team reported that non-exhausted T cell clones in the blood could act as a source of antitumor T...
BC Extra | Jan 28, 2020
Clinical News

FDA clarifies criteria for 'sameness' of gene therapies

In new draft guidance , FDA clarified its criteria for determining whether a gene therapy is the same as an existing treatment when considering its eligibility for Orphan Drug designation and exclusivity. The agency said that...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

A series of incremental but important improvements on the existing gene therapies are starting to address some of the technology’s key limitations. But some argue it will take a major overhaul of manufacturing practices to...
BC Extra | Dec 23, 2019
Company News

Roche’s ex-U.S. deal for Sarepta DMD programs could extend beyond micro-dystrophin gene therapy

After weathering one clinical failure in DMD this fall, Roche broadened its commitment to gene therapy by obtaining ex-U.S. rights to Sarepta’s micro-dystrophin-targeting program in a deal worth more than $1.1 billion up front. Roche...
BC Extra | Dec 19, 2019
Company News

Takeda adds oncolytic viruses to pipeline via Turnstone deal

Takeda has partnered with Turnstone to discover and develop immunotherapies using the biotech’s engineered vaccinia virus platform in a deal that gives the Japanese pharma its first oncolytic virus. Turnstone Biologics Inc. will receive upfront...
BC Extra | Oct 21, 2019
Preclinical News

Liu describes new CRISPR tech, co-founds company to develop it

The latest gene editing technology to emerge from the lab of base editing pioneer David Liu can correct disease-causing mutations without making double-stranded DNA breaks, and without relying on a cell's natural DNA damage repair...
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

Biotech stocks are continuing a downward trend, with all market cap tiers losing value in 3Q19, leading to a total quarterly loss of $88.8 billion. Companies valued at $1-$4.9 billion, $5-$9.9 billion and above $10...
BC Extra | Aug 13, 2019
Company News

Via Synpromics takeout, AskBio adds promoters to gene therapy platform

With the acquisition of Synpromics, well-funded gene therapy developer AskBio has added synthetic promoter technology to its toolkit as it prepares to begin clinical testing of four candidates by YE20. The takeout comes about three...
BC Innovations | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
BC Innovations | Aug 8, 2019
Translation in Brief

A cool menthol switch for gene expression

ETH Zurich researchers have created a synthetic gene circuit activated by topical menthol to switch on gene expression and protein production in engineered cells. In a July Nature Medicine paper , the team used the circuit...
Items per page:
1 - 10 of 622
BioCentury | Feb 29, 2020
Translation in Brief

Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation

Genentech identifies blood as source of antitumor T cells   In a Nature article , a Genentech Inc. team reported that non-exhausted T cell clones in the blood could act as a source of antitumor T...
BC Extra | Jan 28, 2020
Clinical News

FDA clarifies criteria for 'sameness' of gene therapies

In new draft guidance , FDA clarified its criteria for determining whether a gene therapy is the same as an existing treatment when considering its eligibility for Orphan Drug designation and exclusivity. The agency said that...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

A series of incremental but important improvements on the existing gene therapies are starting to address some of the technology’s key limitations. But some argue it will take a major overhaul of manufacturing practices to...
BC Extra | Dec 23, 2019
Company News

Roche’s ex-U.S. deal for Sarepta DMD programs could extend beyond micro-dystrophin gene therapy

After weathering one clinical failure in DMD this fall, Roche broadened its commitment to gene therapy by obtaining ex-U.S. rights to Sarepta’s micro-dystrophin-targeting program in a deal worth more than $1.1 billion up front. Roche...
BC Extra | Dec 19, 2019
Company News

Takeda adds oncolytic viruses to pipeline via Turnstone deal

Takeda has partnered with Turnstone to discover and develop immunotherapies using the biotech’s engineered vaccinia virus platform in a deal that gives the Japanese pharma its first oncolytic virus. Turnstone Biologics Inc. will receive upfront...
BC Extra | Oct 21, 2019
Preclinical News

Liu describes new CRISPR tech, co-founds company to develop it

The latest gene editing technology to emerge from the lab of base editing pioneer David Liu can correct disease-causing mutations without making double-stranded DNA breaks, and without relying on a cell's natural DNA damage repair...
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

Biotech stocks are continuing a downward trend, with all market cap tiers losing value in 3Q19, leading to a total quarterly loss of $88.8 billion. Companies valued at $1-$4.9 billion, $5-$9.9 billion and above $10...
BC Extra | Aug 13, 2019
Company News

Via Synpromics takeout, AskBio adds promoters to gene therapy platform

With the acquisition of Synpromics, well-funded gene therapy developer AskBio has added synthetic promoter technology to its toolkit as it prepares to begin clinical testing of four candidates by YE20. The takeout comes about three...
BC Innovations | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
BC Innovations | Aug 8, 2019
Translation in Brief

A cool menthol switch for gene expression

ETH Zurich researchers have created a synthetic gene circuit activated by topical menthol to switch on gene expression and protein production in engineered cells. In a July Nature Medicine paper , the team used the circuit...
Items per page:
1 - 10 of 622